The Appetite Trade

In April 2026, Eli Lilly began selling a small white pill called Foundayo. Taken once a day, it does something the previous generation of blockbuster weight-loss drugs could only do by injection: it quiets the signal that tells the brain it is hungry. Foundayo — generically, orforglipron — is the first oral medicine of its class, and in trials it outperformed the leading oral competitor on both blood sugar and weight loss. It is, by most accounts, a genuine pharmaceutical triumph, the drug that turns weight-loss medicine from a niche of the willing-to-inject into something as easy to take, and as easy to scale, as a daily vitamin.

It has also helped make Eli Lilly the first drugmaker in history worth more than a trillion dollars.

That milestone is the visible part of the story, and the part the market has enthusiastically priced. The invisible part — the part that makes this one of the most consequential and least-understood trades in the entire market — is everything the pill does downstream. Because a drug that makes hundreds of millions of people less hungry is not only a pharmaceutical product. It is a slow, quiet, economy-wide tax on every company whose profits depend on people eating and drinking more than they need to. The appetite trade has two sides. The market is comprehensively long one of them and has barely begun to price the other.

The winner, and the warning inside it

Start with Lilly, because even the triumphant side of this trade contains a warning the trillion-dollar valuation glosses over.

Lilly's numbers are spectacular. Its tirzepatide franchise — Mounjaro for diabetes, Zepbound for obesity — generated roughly $36 billion in 2025, overtaking the Ozempic-and-Wegovy combination of its Danish rival Novo Nordisk. The company has guided to $80–83 billion of total sales in 2026, growth of around 25%, and its shares rose nearly 40% across 2025 on the way past a $1.01 trillion valuation in June 2026. This is real, enormous, profitable growth, powered by a class of drug whose total market is forecast to exceed $90 billion by the early 2030s. And yet there is a sense of proportion worth holding onto: analysts estimate even the new oral blockbuster, Foundayo, will sell on the order of $15 billion a year by 2030 — a stupendous figure, and still only a fraction of a company already valued at a trillion. To justify the price, Lilly does not need one miracle. It needs a permanent assembly line of them.

But look at what happened to the company Lilly passed, because it is the whole risk in miniature. Novo Nordisk invented this market; Ozempic was the drug that made "GLP-1" a household word. And in 2026 Novo's stock is down nearly 40% — almost the exact mirror image of Lilly's gain — after the company warned that its sales and profit would actually decline this year, by 5–13%, as prices fall in the United States and its patents expire across China, Brazil and Canada. Two companies, the same miracle drug class, and a 40-point gap between them in a single year. The lesson is the oldest one in thematic investing, and the most ignored at the top: the theme can be completely real and most of the stocks can still lose. Being early and dominant in GLP-1 did not save Novo. It is worth asking what, exactly, protects Lilly at a trillion dollars.

The answer the bulls give is "better drugs," and for now they are right. But the thing already eroding Novo is coming for everyone, including Lilly, and it has a name: price. A price war has broken out. Self-pay prices have fallen from around $499 a month toward $349; Novo has dangled $199 starter doses; and behind the current products sit roughly 193 obesity therapies in development, an oncoming wave of competition and, eventually, of generics. "GLP-1 drugs are about to go generic for billions of people" is not a distant worry; it is the structural destination of every blockbuster drug, and the more universal these become, the faster the politics and economics push their price toward commodity levels. Lilly at a trillion dollars is priced as the permanent king of a market that is simultaneously exploding in size and collapsing in price per dose. Both of those things are happening at once, and only one of them is in the stock.

The other side of the plate

Now turn the trade over, because this is where the market is genuinely asleep, and where the most durable consequences lie.

If a meaningful fraction of a country stops feeling hungry, the effects ripple outward through every business built on consumption. The research here is no longer speculative. Studies find that GLP-1 users take in around 21% fewer calories and cut grocery spending by roughly 31% at the extreme; even on average, households reduce grocery spending by about 5.3% within six months of starting the drugs. One projection has GLP-1 users accounting for 35% of all food-and-beverage sales by 2030. And the aggregate damage is enormous: analysts estimate the appetite drugs could strip $30–55 billion a year out of the US food and beverage industry by the early 2030s.

That sum has to come from somewhere, and it comes from identifiable places. The most exposed are the businesses that sell exactly what these drugs make people want less of: snacks, confectionery, sugary drinks, fast food, salty and fatty packaged goods — and, strikingly, alcohol, which GLP-1 drugs appear to suppress the craving for as effectively as they suppress hunger. The dairy categories most threatened are the indulgent ones: cheese, butter, ice cream. The agricultural commodities most at risk are corn, soybeans, sugar. On the other side, the relative winners are the makers of protein and the grocers who sell it — Hormel, Tyson, the supermarket chains — along with the functional-ingredient companies positioned for a higher-protein, lower-calorie world.

Here is the asymmetry that should interest a forensic investor. The winner of this trade — Lilly — is a single, enormous, widely-owned stock trading at a trillion-dollar valuation that already assumes its dominance. The losers are diffuse: dozens of food, snack, beverage and alcohol companies, many of them slow-growing "defensive" stocks sitting in income portfolios and dividend funds, whose valuations still largely assume that people will keep eating and drinking the way they always have. The market has eagerly bid up the one obvious beneficiary and has been far slower to mark down the many quiet victims — partly because the erosion is gradual, a percentage point of volume here, a softening of pricing power there, easy to attribute to anything else for years before the trend becomes undeniable. Slow leaks are the hardest for markets to price, which is precisely why they are where the mispricing lives.

The trade the market only half-understands

None of this is a forecast that Lilly collapses or that the snack aisle disappears. Lilly is a genuinely great company with a genuinely great drug, and people will not stop eating; the food giants will adapt, reformulate, push protein and "GLP-1-friendly" portions, and many will be fine. The obesity drugs are, on balance, one of the most beneficial pharmaceutical advances in a generation, and a healthier population is a wonderful thing that happens to be inconvenient for a few income statements.

But as a trade, the appetite theme is being expressed by the market in a strangely one-sided way. It is long the winner at a price that bakes in permanent dominance, while a price war and a generic cliff quietly eat at the very margins that justify the price. And it is far too sanguine about the losers — a slow, compounding, multi-decade drain on the cash flows of the consumer-staples and alcohol companies that millions of conservative investors own precisely because they believe them to be safe and unchanging. The appetite trade is not "buy Lilly." It is a structural repricing of the entire relationship between a population and its own consumption, and almost nothing about that repricing is finished.

The pill is real. The trillion-dollar valuation is real. The hunger it removes is real — and so, dollar for dollar, is the revenue that hunger used to generate, now quietly draining out of a hundred income statements that have not yet been marked to the new reality. The market has bought the company that makes people eat less. It has not yet sold, with anything like the same conviction, the long, unglamorous list of companies that needed them to eat more. That gap — between the eagerly-priced winner and the barely-priced losers, between a drug market exploding in size and imploding in price — is the whole trade. Most of the market is holding exactly one half of it.